01—Abstract
Summary
Summary of the 10-Q filed October 29, 2026. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma reported a sharply higher top line for the third quarter of 2026 while losses narrowed.
Total revenues, net were $353.2 milliona for the three months ended September 30, 2026, compared with $120.7 million a year earlier, driven by net product revenue of $253.3 million for Attruby and a $75.0 million sales milestone under the Bayer License Agreement. Net loss was $60.5 million for the quarter versus $184.9 million a year earlier. Net loss attributable to common stockholders was $83.0 million after $26.3 million of preferred stock dividends and accretion, which reflect the Series A preferred stock issued July 1, 2026.
For the nine months, total revenues were $791.4 millionb and net loss was $382.9 million, against $538.3 million in the prior-year period. The balance sheet and financing activity changed materially. Cash, cash equivalents and marketable securities were $1.54 billion at September 30, 2026, up from $587.5 million at December 31, 2025.
Financing included $933.9 millionc from the Series A preferred stock, $632.5 million of 0.75% convertible notes due 2033, and $933.9 million in preferred proceeds. The company repurchased common stock and holds a $500.0 million share repurchase program, with $325.0 million remaining at quarter end per the filing's table. Total stockholders' deficit narrowed to $1.65 billion from $2.08 billion.
Total debt includes $2.5 billiond of convertible notes and $920.1 million of deferred royalty obligations. The 2027 Notes, $550.0 million principal, are classified as current and mature March 15, 2027. The filing names three NDAs with FDA Priority Review: oral BBP-418 for LGMD2I/R9 with a PDUFA date of November 27, 2026; encaleret for ADH1 with a PDUFA date of May 8, 2027; and low-dose infigratinib for achondroplasia with a PDUFA date of February 4, 2027.
Management states that cash and marketable securities together with product collections should fund operations for at least the next 12 months. Operating cash outflow was $312.6 million for the nine months.
02—Key points
Key Highlights
- Total revenues, net of $353.2 million for Q3 2026 versus $120.7 million in Q3 2025, including $253.3 million of net product revenue and a $75.0 million Bayer sales milestone recognized in license and services revenue.
- Net loss narrowed to $60.5 million for Q3 2026 from $184.9 million in Q3 2025; net loss attributable to common stockholders was $83.0 million after $26.3 million of preferred dividends and accretion.
- Cash, cash equivalents and marketable securities rose to $1.54 billion at September 30, 2026, from $587.5 million at December 31, 2025, aided by $933.9 million of Series A preferred stock and $632.5 million of 2033 convertible notes.
- The $547.0 million of 2027 Notes principal... classified as current; the carrying amount is $548.4 million at September 30, 2026, maturing March 15, 2027.
- Three NDAs have Priority Review with PDUFA dates: BBP-418 (November 27, 2026), infigratinib (February 4, 2027) and encaleret (May 8, 2027).
- Stockholders' deficit improved to $1.65 billion from $2.08 billion at December 31, 2025; total indebtedness is $2.5 billion of convertible notes plus $920.1 million of deferred royalty obligations.
- Operating cash outflow was $312.6 million for the nine months ended September 30, 2026, and the company repurchased 2,616,166 shares under its $500.0 million program at an average price of $66.88.
03—One dollar
Follow one dollar
For each $1.00 of revenue in Q3 FY2026, BridgeBio Pharma lost $0.24.
- Revenue$353.2M100.0%
- Cost of revenue−$20.4M5.8%
- Gross profit$332.7M94.2%
- Operating costs−$344.4M97.5%
- Operating income−$11.6M3.3%
- Interest, other & tax−$71.4M20.2%
- Net income−$83.0M23.5%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2026filed October 29, 2026Financial Statements
Q3 FY2026 against Q3 FY2025
| Line item | Q3 FY2026Q3 FY2025 | Change |
|---|---|---|
| Revenue | $353.17M$120.70M | +192.6% |
| Cost of Revenue | $20.45M$6.56M | +211.6% |
| Gross Profit | $332.72M$114.14M | +191.5% |
| R&D Expenses | $143.51M$112.87M | +27.1% |
| SG&A Expenses | $200.85M$137.62M | +45.9% |
| Operating Expenses | $364.81M$265.90M | +37.2% |
| Operating Income | -$11.64M-$145.20M | +92.0% |
| Net Income | -$83.00M-$182.74M | +54.6% |
| EPS (Basic) | $-0.42$-0.95 | +55.8% |
| EPS (Diluted) | $-0.42$-0.95 | +55.8% |
| Shares Outstanding (Basic) | 196.03M191.85M | +2.2% |
| Shares Outstanding (Diluted) | 196.03M191.85M | +2.2% |
05—Questions
Frequently Asked Questions
How much did revenue grow and what drove it?
Total revenues, net were $353.2 million for the three months ended September 30, 2026, up $232.5 million from $120.7 million a year earlier. Net product revenue rose $145.2 million, primarily from continued Attruby commercial expansion driven by patient demand. License and services revenue rose $71.0 million, mainly from a $75.0 million sales milestone under the Bayer License Agreement, and royalty revenue rose $16.2 million, largely from Beyonttra sales in the EU and Japan.
What is the status of the preferred stock and its effect on common stockholders?
On July 1, 2026, the company issued 933,900 shares of Series A Cumulative Convertible Participating Preferred Stock for $933.9 million. Dividends accrue at an initial 7.00% rate and the company has elected to pay them in cash. For Q3 2026, preferred dividends and accretion of $26.3 million were added to the loss attributable to common stockholders, which was $83.0 million. The preferred stock is convertible into 6,777,704 common shares at an initial conversion price of $137.79.
How much debt does BridgeBio have and when does it come due?
As of September 30, 2026, convertible senior notes had a net carrying amount of $2.5 billion across four series: $548.4 million of 2027 Notes maturing March 15, 2027, $742.4 million of 2029 Notes, $566.0 million of 2031 Notes and $620.5 million of 2033 Notes. Deferred royalty obligations totaled $920.1 million. The 2027 Notes are classified as current liabilities. The filing states that the 2027 Notes became convertible during a limited period from October 1, 2026 through December 14, 2026.
What regulatory catalysts does the filing identify?
The filing reports that the FDA accepted three NDAs and granted Priority Review. The BBP-418 NDA for LGMD2I/R9 has a PDUFA target action date of November 27, 2026. The low-dose infigratinib NDA for achondroplasia has a PDUFA date of February 4, 2027, and the encaleret NDA for ADH1 has a PDUFA date of May 8, 2027.
Is the company funded for the next year?
Management states that its cash, cash equivalents and marketable securities, together with increasing cash collections from Attruby sales and collaboration revenue, will fund operations for at least the next 12 months from the filing date. The company also notes that operating plans may change and that it may need additional funding sooner, through equity, debt or collaborations. Operating cash outflow was $312.6 million for the nine months ended September 30, 2026.
06—Continue